Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|October 28, 2025
Emerging Agents and Paradigm Shifts in Gynecologic Cancer: Expert Takeaways From ESMO 2025
Author(s)Courtney Flaherty
Fact checked by: Chris Ryan
Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.
Advertisement
Advertisement
The
Related to this article
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Advertisement
Advertisement